Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports

Goodwin, Shirley; Glenny, Robb W.

doi:10.1001/archinte.152.7.1521

Cited by 29 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histological changes in pulmonary tissue, such as infl ux of infl ammatory cells and interstitial and alveolar infl ammation with increased numbers of eosinophils, support the theory of an immunologic pathogenesis [1] . The mechanism of nimesulide-induced PIE is unknown; a hypersensitive reaction is suggested by the occurrence of eosinophilia in the peripheral blood and airways.…”

Section: Discussionmentioning

confidence: 59%

“…Several reports have indicated that a variety of nonsteroidal anti-infl ammatory drugs (NSAIDs), such as naproxen [1] , diclofenac [2] , indomethacin [3] , sulindac [4] and fenbufen [5] , can cause pulmonary infi ltrates with eosinophilia (PIE). The prevalence of this side effect is 652 chest X-ray fi lm revealed scattered alveolar infi ltrates over the right upper, middle and left upper lobes ( fi g. 1 a).…”

Section: Introductionmentioning

confidence: 99%

“…

likely underestimated because of the extensive use of these drugs and the relatively benign course of the PIE syndrome [1] . Nimesulide is a member of a new class of NSAIDs that is selective for cyclooxygenase-2 [6] .

…”

mentioning

confidence: 99%

See 2 more Smart Citations

Pulmonary Infiltrates with Eosinophilia Induced by Nimesulide in an Asthmatic Patient

Perng

Su²,

Tseng³

et al. 2005

Respiration

View full text Add to dashboard Cite

We report a case of pulmonary infiltrates with eosinophilia (PIE) induced by nimesulide in an asthmatic patient on regular inhaled corticosteroid treatment. A high level of eosinophils in induced sputum was detected. No evidence of bacterial or fungal infection was observed. The patient responded rapidly to corticosteroid treatment. Rechallenge with nimesulide induced blood and sputum eosinophilia, confirming our diagnosis. Nimesulide, though it is a relatively safe drug to use in aspirin-sensitive asthmatics, may (like other nonsteroidal anti-inflammatory drugs) cause PIE in asthmatic patients and thus should be used cautiously.

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary Infiltrates with Eosinophilia Induced by Nimesulide in an Asthmatic Patient

Perng

Su²,

Tseng³

et al. 2005

Respiration

View full text Add to dashboard Cite

show abstract

“…Two in vivo indicators of chronic NSAID administration, eosinophilia (Ͼ0.24 eosinophils/10 3 cells/l; Ref. 44), and a drop in plasma PGE 2 levels (45), appeared in mice fed the celecoxib-supplemented diets. After Ͼ2 months, eosinophilia was present in mice fed diets supplemented with 1000 and 1500 ppm celecoxib.…”

Section: Resultsmentioning

confidence: 99%

Combination of a Poxvirus-Based Vaccine with a Cyclooxygenase-2 Inhibitor (Celecoxib) Elicits Antitumor Immunity and Long-Term Survival in CEA.Tg/MIN Mice

Zeytin¹,

Patel

Rogers

et al. 2004

Cancer Research

View full text Add to dashboard Cite

The present study was designed to determine whether: (a) chronic administration of dietary celecoxib (Celebrex), a potent nonsteroidal antiinflammatory drug, which targets the cyclooxygenase-2 (COX-2) enzyme, negatively impacts host immunity; and (b) celecoxib can be coupled with a poxvirus-based vaccine to impact tumor burden in a murine tumor model of spontaneous adenomatous polyposis coli. Naive mice fed the celecoxib-supplemented diets developed eosinophilia with lowered plasma prostaglandin E 2 levels and reduced COX-2 mRNA expression levels in their splenic T cells. The results suggest that the administration of a recombinant poxvirusbased vaccine is compatible with celecoxib, and this combined chemoimmuno-based approach might lead to an additive therapeutic antitumor benefit not only in patients diagnosed with familial adenomatous polyposis but, perhaps, in other preventive settings in which COX-2 overexpression is associated with progression from premalignancy to neoplasia.

show abstract

“…During a 3-4 month time period, the general health status of individual mice was closely monitored. Chronic exposure to celecoxib was indicated by the appearance of eosinophilia (>0.24 eosinophils per 10 3 cells/μl) [104] and a drop in plasma PGE 2 levels [105]. Despite those changes, individual weight gain and CBC/differential counts were similar for mice whether or not they were fed a celecoxib-supplemented diet.…”

Section: Future Directions: Combination Therapies: Cancer Vaccine Andmentioning

confidence: 99%

Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: Evaluation of CEA-based cancer vaccines

Hance

Zeytin

Greiner

2005

Mutation Research/Fundamental and Molecular Mechanisms of Mutag

View full text Add to dashboard Cite

In recent years, investigators have carried out several studies designed to evaluate whether human tumor-associated antigens might be exploited as targets for active specific immunotherapy, specifically human cancer vaccines. Not too long ago such an approach would have been met with considerable skepticism because the immune system was believed to be a rigid discriminator between self and non-self which, in turn, protected the host from a variety of pathogens. That viewpoint has been challenged in recent years by a series of studies indicating that antigenic determinants of self have not induced absolute host immune tolerance. Moreover, under specific conditions that evoke danger signals, peptides from self-antigen can be processed by the antigen-presenting cellular machinery, loaded onto the major histocompatibility antigen groove to serve as targets for immune intervention. Those findings provide the rationale to investigate a wide range of tumor-associated antigens, including differentiation antigens, oncogenes, and tumor suppressor genes as possible immune-based targets. One of those tumor-associated antigens is the carcinoembryonic antigen (CEA). Described almost 40 years ago, CEA is a M r 180-200,000 oncofetal antigen that is one of the more widely studied human tumor-associated antigens. This review will provide: (i) a brief overview of the CEA gene family, (ii) a summary of early preclinical findings on overcoming immune tolerance to CEA, and (iii) the rationale to develop mouse models which spontaneously develop gastrointestinal tumors and express the CEA transgene. Those models have been used extensively in the study of overcoming host immune tolerance to CEA, a self, tumor-associated antigen, and the experimental findings have served as the rationale for the design of early clinical trials to evaluate CEA-based cancer vaccines.

show abstract

Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports

Cited by 29 publications

References 13 publications

Pulmonary Infiltrates with Eosinophilia Induced by Nimesulide in an Asthmatic Patient

Pulmonary Infiltrates with Eosinophilia Induced by Nimesulide in an Asthmatic Patient

Combination of a Poxvirus-Based Vaccine with a Cyclooxygenase-2 Inhibitor (Celecoxib) Elicits Antitumor Immunity and Long-Term Survival in CEA.Tg/MIN Mice

Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: Evaluation of CEA-based cancer vaccines

Contact Info

Product

Resources

About